

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07K 16/18, C12P 21/08</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/23815</b> (43) International Publication Date: <b>8 August 1996 (08.08.96)</b>
<p>(21) International Application Number: <b>PCT/US96/00957</b></p> <p>(22) International Filing Date: <b>29 January 1996 (29.01.96)</b></p> <p>(30) Priority Data: <b>08/381,264</b>      <b>31 January 1995 (31.01.95)</b>      <b>US</b></p> <p>(60) Parent Application or Grant (63) Related by Continuation <b>US</b>      <b>08/381,264 (CON)</b> <b>Filed on</b>      <b>31 January 1995 (31.01.95)</b></p> <p>(71) Applicant (for all designated States except US): <b>ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>HEATH, William, F., Jr. [US/US]; 11214 Tufton Street, Fishers, IN 46038 (US). MANETTA, Joseph, V. [US/US]; 8134 North Richardt Avenue, Indianapolis, IN 46256 (US). SHIELDS, James, E. [US/US]; 17808 Grassy Branch Road, Noblesville, IN 46060 (US).</b></p>	<p>(74) Agents: <b>MACIAK, Ronald, S. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</b></p> <p>(81) Designated States: <b>AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> <i>With international search report.</i></p>	
<p>(54) Title: <b>OB GENE PRODUCT ANTIBODIES</b></p> <p>(57) Abstract</p> <p>Novel monoclonal and polyclonal antibodies that selectively bind to various biologically active fragments and fragment analogs of the mammalian <i>ob</i> gene product are claimed. The invention is useful for purifying the <i>ob</i> gene product, its fragments, and analogs. The claimed antibodies are also useful in diagnostic tests to monitor therapy.</p> <p style="text-align: center; font-size: 2em; font-weight: bold; transform: rotate(-10deg);">BEST AVAILABLE COPY</p>		